220334-14-5

Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling[1][2].

Store at -20°C

[1] Ghamande SA, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111(1):89-94. DOI:10.1016/j.ygyno.2008.06.028
[2] Finlayson M. Modulation of CD44 Activity by A6-Peptide. Front Immunol. 2015;6:135. Published 2015 Mar 30. DOI:10.3389/fimmu.2015.00135
[3] Piotrowicz RS, et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther. 2011;10(11):2072-2082. DOI:10.1158/1535-7163.MCT-11-0351